/ Regulation / Is GHK-Cu legal?
Is GHK-Cu legal? FDA status of copper peptides, explained
Contents
Prepared by: Research Desk. Sources are linked for verification.
The short answer is that it depends on what you mean by “GHK-Cu”. The copper-binding tripeptide glycyl-L-histidyl-L-lysine shows up in two very different worlds. In one it is an ingredient in creams and serums. In the other it is a powder or solution meant for injection. U.S. law handles those two worlds differently, and much of the confusion online comes from blurring them.
This explainer walks through the three rule sets that matter: cosmetic law, drug law, and the pharmacy-compounding rules. We also flag what we could not confirm.
1. As a cosmetic ingredient: lawful, but not “approved”
The FDA does not pre-approve cosmetic products or most cosmetic ingredients. Color additives are the main exception. A moisturizer containing copper tripeptide-1 (the INCI name you will usually see on labels) can be sold legally without an FDA approval, provided it is safe under its labelled conditions of use and is properly labelled.
Since the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), cosmetic companies have extra duties. These include facility registration, product listing, adverse-event reporting and safety substantiation [2]. None of these is an approval. So when a product page says “FDA-approved copper peptides”, that is a red flag. That phrase has no meaning for a cosmetic.
2. The claim decides whether it is a drug
The FDA’s guidance on the cosmetic/drug line is clear. A product’s intended use decides its category, and intended use is shown largely by the claims made for it [1]. “Improves the look of fine lines” is a typical cosmetic claim. Claims about wound repair, hair regrowth or collagen “repairing” damaged tissue are claims about affecting the structure or function of the body, or about disease. Claims like those can turn the same serum into an unapproved new drug.
This matters for GHK-Cu more than for most ingredients, because so much of the published research is about wound healing and tissue repair [3][4]. Brands that repeat those findings in their marketing may be crossing from cosmetic into drug territory, even if the formula itself is unchanged.
3. Injectable GHK-Cu: the compounding question
Injectable copper peptide is not an FDA-approved drug for any use. Outside of clinical trials, the main legal route for an unapproved active ingredient to reach a person is pharmacy compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounders may only use bulk substances that meet certain criteria, including nominated substances under FDA’s interim policies.
FDA keeps a public page of bulk drug substances that “may present significant safety risks” [5]. On the version we reviewed (content current as of 22 April 2026), “GHK-Cu (for injectable routes of administration)” appears in the section listing substances that were previously in category 2 and whose nominations were later withdrawn by the nominators. FDA’s text still sets out its concern. Compounded injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities”, and “there are limited data in humans to inform safety-related considerations” [5].
Two things follow from that:
The FDA’s safety concern was specific to injection. It did not express the same concern about topical cosmetic use.
“Withdrawn from category 2” does not mean “approved”. It means the nomination that put it there was pulled. Injectable GHK-Cu still has not been shown safe and effective through the FDA drug-approval process.
What about “research use only” vials?
Websites selling peptide vials labelled “for research use only, not for human consumption” operate outside both the cosmetic and the drug system. Products like these have no FDA review of identity, purity, sterility or dose. The agency’s concerns about aggregation and impurities [5] apply with even more force to products made with no pharmacy oversight. We do not link to these sellers and never will.
Outside the United States
Rules differ by country. In the European Union, cosmetic ingredients are governed by the Cosmetics Regulation and the CosIng ingredient database, and medicinal claims trigger medicines law. We have not yet completed a verified country-by-country review, so we don’t make claims about other jurisdictions here. Outside the U.S., national regulators set the rules.
The bottom line
Topical copper peptides in cosmetics: legal to sell in the U.S. without approval, as long as they are marketed with cosmetic claims.
Disease or repair claims: can make the product an unapproved drug.
Injectable GHK-Cu: not approved. FDA has documented immunogenicity and impurity concerns, and there are limited human safety data.
Status checked: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.